Bristol-Myers Squibb Company (BMY)

64.72
+0.46(+0.72%)
  • Volume:
    6,841,176
  • Bid/Ask:
    64.71/64.72
  • Day's Range:
    64.25 - 65.22

BMY Overview

Prev. Close
64.26
Day's Range
64.25 - 65.22
Revenue
42.81B
Open
64.43
52 wk Range
54.08 - 67.13
EPS
-2.78
Volume
6,841,176
Market Cap
144.66B
Dividend (Yield)
1.96 (3.03%)
Average Vol. (3m)
11,871,994
P/E Ratio
-
Beta
0.61
1-Year Change
2.55%
Shares Outstanding
2,231,000,000
Next Earnings Date
Jul 29, 2021
What is your sentiment on Bristol-Myers Squibb Company?
or
Vote to see community's results!

Bristol-Myers Squibb Company News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellBuyBuyStrong Buy
SummaryStrong SellStrong SellBuyStrong BuyStrong Buy

Bristol-Myers Squibb Company Company Profile

Bristol-Myers Squibb Company Company Profile

Employees
30250

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Read More
  • buy buy.
    0
    • buy buy buy
      0
      • Bought @ 62.50, this is just a bump in the road even in the medium term.
        0
        • A few more weeks, as the technicals are aligning  quite nicely. It will move higher above 65 after.
          1
          • Looks like a nice buy hold
            0
            • Support established in the 60.5 rang considering how undervalued this stock based on its growth story, etc (forward PE <9)
              1
              • Technically this is setting up for a big move up.
                0
              • volume good today, let's what final week brings
                0
            • Again in the after hour there was a huge movment, 1,7 million shares ;) A very nice buy
              0
              • Szabolcs Dávid hahahaha :) whoever did sees nice potential as I do
                0
              • Buffet increased also his portfolio of this stock. Good news and normal price increase.
                0
              • Szilvia Vamos I still wait for a breakout and a backtest before buying more.
                0
            • Bought some more.
              0
              • Ciprian Gal I guess something is going on, in the after hours there was **** movment, that's not normal.
                0
              • 900.000+ share movement
                0
              • Ciprian Gal source?
                0
            • Additional day with a bargain price
              0
              • Let's add some more
                0
                • Short interest is high at the moment.
                  0
                  • what gives? disgruntled former Celgene shareholders perhaps. They are ***ed because their CVR's went down the tubes :)
                    0
                • moving nicely in an ascending channel
                  0
                  • moving nicely in an ascending channel
                    0
                    • Good news - BMY finally wins FDA approval for lymphoma treatment Breyanzi https://www.biopharmadive.com/news/bristol-myers-liso-cel-fda-approval-car-t/594660/
                      0
                      • prioe at 100 day support
                        0
                        • Great earnings, beating estimates. Buy and hold forever
                          0
                          • For the future. Great upside potential in earnings and dividends. Share buyback programme announced will lead to a considerably EPS growth and this do not even calculates the real growth
                            0
                          • Buy the boring stock, sustainable growth rate means stable profit.  The price will catch up with real value soon.
                            0
                          • I bought this before earnings and keeps going down,... i thought it was gonna do better with those good numbers.
                            0
                        • haters hate.....I've been in this since $40.....I enjoy boring stocks bc they tend to remain profitable for more than 4 days....
                          0
                          • only reason to buy more...winds will change soon.
                            0
                        • Is this a head and shoulders formation on the monthly chart?
                          0
                          • VERY slow moving a complete nothing burger - too many reds, not enough recovery - in the last month, for a $60 ******stocks, it moved a net $0.51 cents to the NEGATIVE direction - AND, for that reason, I am out !
                            1
                            • this is a very boring stock.
                              0
                              • I just bought some more right now.
                                1
                              • me too, the momentum will come ;) Fundamentals are amazing
                                0
                              • Ciprian Gal You love misery! lol
                                1
                            • forward p/e for 2021 is about 10. very cheap with dividends and share buybacks. you can see why it was a clear buffet pick. long term hold.
                              0
                              • so keep your money hostage for some false "maybe/maybe not" hope.. interesting how people think.
                                0
                            • Should i buy it ?
                              0
                              • I bought more today.
                                0
                              • bullish close today
                                0
                              • Time is now. I'm in at $65.25 Yea!
                                0
                            • ARK Invest just bought 700044 shares. I'm in.
                              0
                              • Too soon, wait for more pronounced pull back.
                                0
                              • ARK Largest shareholders include Morgan Stanley, LPL Financial LLC, Bank Of America Corp /de/, Raymond James & Associates, Raymond James Financial Services Advisors, Inc., Royal Bank Of Canada, Northwestern Mutual Wealth Management Co, HighTower Advisors, LLC, Merit Financial Group, LLC, and Cambridge Investment Research ...
                                0
                            • BMY hasn't gone anywhere in 5 years. The stock is highly undervalued, it will outperform the market in 2021, the patient will reap the benefits.
                              0
                              • The ‘patient’ has been in tribulation for five years. Rejoicing in hope for BMY to deliver the proper medicine for the poor ‘patient’
                                0
                            • When is this garbage going to shoot up?
                              1
                              • just now, but patience my padme
                                0
                              • top pick. gs picked as outstanding buy
                                0
                              • after January 6
                                0
                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.